Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC

Size: px
Start display at page:

Download "Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC"

Transcription

1 Taking Laboratory Coding for a Spin Corrie Alvarez, CPC, CPMA, CPC-I, CEDC

2 Agenda Overview of Laboratory Discuss Common Laboratory Terms Coding Guidelines Review Drug Testing, Anatomical Pathology Discuss Molecular Pathology and MAAA Testing Proper Use of Common Modifiers Billing and Coding Challenges

3 Laboratory World Competitive and Complex Highly Regulated Departments: Hematology, Immunology, Microbiology, Cytopathology

4 Laboratory Terms Analyte The sample being analyzed. For blood glucose, the analyte would be glucose

5 Laboratory Terms Assay An analysis done to determine the presence and/or amount of a substance in a source. An assay may be done to determine the level of thyroid hormones in the blood

6 Laboratory Terms Aliquot In Latin, terms means some or several. - a portion of a total amount of a solution Qualitative -vs- Quantitative

7 Billing/Coding Guidelines Testing must be ordered by an authorized provider, must be resulted, must be reported. Diagnoses must come from the ordering provider or their authorized designee.

8 Drug Testing Drug Assays Dependent on purpose and type of patient results obtained. Presumptive Drug Class Screening Drug Class A/Drug Class B Chain-of-Custody Definitive Drug Testing

9 Therapeutic Drug Assays Code Series Drug testing performed to monitor clinical response to a known, prescribed medication Examples: Cyclosporine, Digoxin, Phenobarbital, Vancomycin

10 Cytopathology What is Cytopathology? Pap Smears Bethesda System -standard description of results Cervical changes may be called a squamous intraepithelial lesion (SIL), cervical intraepithelial neoplasia (CIN) or dysplasia.

11 Cytopathology SIL is used to describe pap results. CIN and dysplasia are used to describe the actual changes in cervical cells Squamous intraepithelial lesion (SIL) term used to describe pre-cancer changes.

12 Cytopathology Normal (negative) -no signs of cancer or pre-cancer Atypical squamous cells of undetermined significance (ASC-US) - cellular changes are found - most common abnormal result

13 Cytopathology Squamous intraepithelial lesion (SIL) -Abnormal changes found in the cells. Almost always sign of HPV infection. May indicate pre-cancer.

14 Cytopathology LSIL -low grade. Very common. Usually resolves on it s own without treatment. HSIL -more serious. Can lead to Carcinoma in situ. CIS is a severe form of HSIL.

15 Cytopathology Atypical squamous cells (ASCUS) Need further testing if persistent. 4-6 months repeat pap

16 Cytopathology Atypical glandular cells (AGC) -cell changes are seen that suggest pre-cancer of the upper part of cervix or uterus Cancer -abnormal cells may be spread deeper into cervix or other tissues

17

18

19

20

21

22

23 Incidence of Cervical Cancer In the U.S., it is estimated that: Annually, about 12,990 new cases will be diagnosed with invasive cervical cancer Over 4,120 women will die of cervical cancer

24 Annual Estimated Costs in US The approximate annual cost of cervical cancer is $181.5 million to $393 million The annual approximate cost of cervical cell abnormalities is between $2.25 billion and $4.6 billion

25 Anatomical Pathology Surgical Pathology Decalcification Special Stains Group l Special Stains Group II Consultations Consultations Tissue blocks/frozen sections

26 Surgical Specimens Gross examination Gross and microscopic Successive codes have an increase level of complexity Colon Biopsies: 88304, 88305, 88307, 88309

27 Additional Surg Path Services Decalcification Special Stains 88312, per stain, per specimen Example: 1. One specimen with multiple slides for that specimen, iron stain ordered = x1

28 Surgical Pathology Consults Consult and report on referred slides, prepared elsewhere: Consult and report on referred material requiring preparation of slides: Consult, comprehensive, with review of records, specimens with report: Pathology consult during surgery: 88329

29 Pathology Consultations Pathology Consultation during surgery first tissue block, with frozen section(s), single specimen each additional tissue block from frozen section(s)

30 Molecular Pathology What is it? Medical laboratory procedures involving the analyses of nucleic acid to detect variants in genes that may be indicative of germline (e.g., constitutional disorders) or somatic (e.g., neoplasia) conditions or to test for histocompatibility antigens (e.g., HLA) What does this mean?

31 Terms to Know ACMG American College of Medical Genetics & Genomics ACOG American Congress of OB/GYNs Alleles One member of a pair or series of genes that occupy a specific position on a specific chromosome

32 Terms to Know Deoxyribonucleic acid DNA Analyte A substance undergoing analysis Assay Determination of the amount of a particular constituent of a mixture

33 Terms to Know Analyte A substance undergoing analysis Assay Determination of the amount of a particular constituent of a mixture Deoxyribonucleic acid DNA

34 Terms to Know Gene The biologic unit of heredity, self-reproducing and located at a definite position (locus) on a particular chromosome Germline The sequence of cells in the line of direct descent from zygote to gametes, as opposed to somatic cells (all other body cells). Mutations in germline cells are transmitted to offspring; those in somatic cells are not.

35 Terms to Know Histocompatibility Antigens (HLA) A molecule occurring on the surface of tissue cells that can take several different forms Nucleic Acids The building blocks of living organisms. These allow the transfer of gentic information to be passed from one generation to the next Variants-a deviation from the normal Common Variants-These typically fit the definition of mutation

36 Let s Look at Definition Again Medical laboratory procedures involving analyses of nucleic acid to detect variants in gens that may be indicative of germline (e.g., constitutional disorders) or somatic (e.g., neoplasia) condition or to test for histocompatibility antigens (e.g., HLA) FEEL BETTER???

37 What was the Need? Human Genome Project Completed in billion dollars Medical Ethics

38 MoPath Starting in 2013, MoPath codes were required to be analyte specific Prior to 2013, a stacking CPT method was used reflecting the test methodology only Tier 1 and Tier 2

39 Tier 1 Represents gene-specific and genomic procedures Code selection based on the specific gene being analyzed Gene descriptors according to HUGO

40 Tier 1 Gene name abbreviation is listed first Example: CFTR Full gene name italicized in parentheses second Example: Cystic Fibrosis Transmembrane Conductance Regulator Not all conditions represented Reference guidelines for additional details, instructions and/or definitions

41 Tier 1 9 new codes, 3 revisions were added in 2016 Watch out for exclusions, add on codes and out of sequence codes Example BRCA testing do not report with 81211, 81213, 81214, 81216

42 Tier 2 Consists of 9 CPT codes (17 pages). Not commonly ordered. Rare diseases Arranged by level of technical resources and interpretive work by the physician

43 Genomic Sequencing & MAAA Used as inputs into algorithmic analysis to derive a single result-numeric score/index/probability 81500/81503 Ovarian cancer risk score Endocrinology Diabetes risk score

44 81503 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and pre-albumin), utilizing serum, algorithm reported as a risk score Pre-surgical blood test Evaluates 5 biomarkers (listed above) Single score between 0.0 and 10.0 Established thresholds Higher scores allow the referral to a GYN Oncologist

45 81506 Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-crp, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score

46 Appendix O Set of administrative codes for MAAA procedures Proprietary name and Clinical Laboratory or Manufacturer Code Descriptor format MAAA without Tier 1 listed here with 4 numbers followed by the letter M. MAAA Unlisted code 81599

47 MAAA AMA does not recommend pricing for these codes Other codes are used for payment of underlying tests on which the MAAA is done No allowable for algorithms.

48 Modifiers Modifier 26 Professional Component Modifier 59 Distinct Procedural Service Modifier 90 Reference (Outside) Testing Modifier 91 Repeat Clinical Lab Test Modifier 92 Alternative Lab Platform Test

49 Billing & Coding Challenges High volume, low dollar Medical necessity edits Client and patient education Federal and state regulations

50 Medicare/Payer MLCP PSA, Total Medicare will only pay for this test for the following conditions: C61, C67.5, C77.4, C77.5, C D07.5, D40.0, D49.5. N13.9, N32.0, N40.0, N40.1 R31.0, R32, R35.1, R39.16 Z85.46 (total of 38 dx codes)

51 Questions?

52 THANK YOU!!

Understanding Your Pap Test Results

Understanding Your Pap Test Results Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities

More information

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN. CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee

More information

BC Cancer Cervix Screening 2015 Program Results. February 2018

BC Cancer Cervix Screening 2015 Program Results. February 2018 BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...

More information

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Cervical Screening for Dysplasia and Cancer in Patients with HIV Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase

More information

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013 Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely

More information

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health

More information

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in

More information

Clinical Practice Guidelines June 2013

Clinical Practice Guidelines June 2013 Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early

More information

Should Anal Pap Smears Be a Standard of Care in HIV Management?

Should Anal Pap Smears Be a Standard of Care in HIV Management? Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV

More information

Colposcopy. Attila L Major, MD, PhD

Colposcopy. Attila L Major, MD, PhD Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000

More information

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates

More information

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer

More information

Pathology and Laboratory

Pathology and Laboratory Pathology and Laboratory CPT CPT copyright 2011 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by

More information

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent

More information

Eradicating Mortality from Cervical Cancer

Eradicating Mortality from Cervical Cancer Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

What is a Pap smear?

What is a Pap smear? Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years

More information

Making Sense of Cervical Cancer Screening

Making Sense of Cervical Cancer Screening Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because

More information

News. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM

News. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND

More information

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted? CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses

More information

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION HPV Vaccine FAST FACTS: Payer & Reimbursement Strategies Medicaid: Many state Medicaid programs cover the HPV vaccine, though this coverage varies by state. Information on coverage can be found through

More information

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This

More information

Cytology Report Format

Cytology Report Format Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College

More information

Chapter 10: Pap Test Results

Chapter 10: Pap Test Results Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the

More information

Done by khozama jehad. Neoplasia of the cervix

Done by khozama jehad. Neoplasia of the cervix Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus

More information

Understanding My Pap Test Results

Understanding My Pap Test Results Form: D-8766 Understanding My Pap Test Results For patients of the Gynecology Oncology Clinic Read this pamphlet to learn more about: why you are having a Pap test how to understand your test results what

More information

Pap plus HPV every 3 years with screening stopped at 65, 75 and 100 years; Pap plus HPV every 2 years with screening stopped at 65, 75 and 100 years.

Pap plus HPV every 3 years with screening stopped at 65, 75 and 100 years; Pap plus HPV every 2 years with screening stopped at 65, 75 and 100 years. Benefits and costs of using HPV testing to screen for cervical cancer Mandelblatt J S, Lawrence W F, Womack S M, Jacobsen D, Yo B, Hwang Y, Gold K, Barter J, Shah K Record Status This is a critical abstract

More information

Your Colposcopy Visit

Your Colposcopy Visit Introduction Welcome to the colposcopy clinic. This booklet tells you about. The colposcopy examination.. Tests that are done in the colposcopy clinic.. What these tests look for Take a few minutes to

More information

Cytology and Surgical Pathology of Gynecologic Neoplasms

Cytology and Surgical Pathology of Gynecologic Neoplasms Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632

More information

Understand Your Results

Understand Your Results Understand Your Results The Pap test takes little time and may save your life. This simple screening test checks for cell changes in the cervix, the opening of the uterus. If your Pap results were abnormal,

More information

Cervical Precancer: Evaluation and Management

Cervical Precancer: Evaluation and Management TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of

More information

EU guidelines for reporting gynaecological cytology

EU guidelines for reporting gynaecological cytology EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize

More information

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases

More information

PAP smear. (Papanicolaou Test)

PAP smear. (Papanicolaou Test) PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European

More information

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care

More information

Multimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy

Multimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy Multimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy L Twiggs, T De Santis, NM Chaktoura, D Ferris, L Flowers, M Lashgari, E Wilkinson, S Bambot, A Agrawal, and D Mongin EUROGIN

More information

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives

More information

National Cervical Screening Program MBS Item Descriptors

National Cervical Screening Program MBS Item Descriptors National Cervical Screening Program MBS Item Descriptors Item Item descriptor 73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer

More information

2017 NBCCEDP Allowable Procedures and Relevant CPT Codes

2017 NBCCEDP Allowable Procedures and Relevant CPT Codes 2017 NBCCEDP Allowable Procedures and Relevant CPT Codes Listed below are allowable procedures and the corresponding suggested Current Procedural Terminology (CPT) codes for use in the National Breast

More information

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

chapter 4. The effect of oncogenic HPV on transformation zone epithelium chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence

More information

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology

More information

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea

More information

Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index

Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila

More information

Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing

Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics

More information

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006 anitoba Cervical Cancer Screening Program Operations & Statistical Report 2005 and 2006 1 MCCSP 2005-2006 Report ANITOBA CERVICAL CANCER SCREENING PROGRAM 2005 and 2006 Operations & Statistical Report

More information

Chapter 8. Summary. Chapter 8. Summary

Chapter 8. Summary. Chapter 8. Summary Chapter 8 Chapter 8 Summary Summary Summary In CHAPTER 1 an introduction to several aspects of cervical cancer, HPV and their relation with immunology is given. It took almost one-and-a-half centuries

More information

Cervical Cancer Screening

Cervical Cancer Screening Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)

More information

WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1

WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1 WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1 HOW TO CITE THIS ARTICLE: G. J. Vani Padmaja. Well Woman Clinic-Screening Program for Cervical Carcinomas. Journal of Evolution

More information

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Management Algorithms for Abnormal Cervical Cytology and Colposcopy Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent

More information

Observership Program Anatomical Pathology

Observership Program Anatomical Pathology Observership Program Anatomical Pathology Pathology is the study and diagnosis of diseases through examination of organs, tissues, cells and bodily fluids. Pathology is a unique medical specialty in that

More information

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Manager @ Harris Health System What is a Pap Smear and when is it recommended? Pap smear The Pap smear is a screening

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,

More information

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical

More information

An Introduction to CPT Coding

An Introduction to CPT Coding An Introduction to CPT Coding Michael L. Talbert, M.D., FCAP Copyright 2005 College of American Pathologists (CAP). All rights reserved. Participants are permitted to duplicate the materials for educational

More information

Associate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran.

Associate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran. Assessment of Visual Inspection with Acetic Acid (VIA) as a Screening Test for Cervical Neoplasia in Comparison with Cytologic Screening in Imam Khomeini Hospital F. Ghaemmaghami, MD Associate Professor

More information

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology United States and Canadian Academy of Pathology 102 nd Annual Meeting Baltimore, Maryland Christina S. Kong, M.D.

More information

Cervical Cancer Screening Guidelines Update

Cervical Cancer Screening Guidelines Update Frontier AIDS Education and Training Center Cervical Cancer Screening Guidelines Update Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics Frontier AETC, Medical Program Director

More information

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

!#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ !"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015 Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results

More information

Management of Abnormal Cervical Cytology and Histology

Management of Abnormal Cervical Cytology and Histology Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline

More information

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is

More information

PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE

PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim

More information

Quarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology

Quarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology Legacy LabAdvisor Quarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology Edition 3 Inside this issue New Testing Developments.... 2 Test Algorithm...

More information

The Korean Journal of Cytopathology 13(1): 14-20, 2002

The Korean Journal of Cytopathology 13(1): 14-20, 2002 13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous

More information

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018 Document Title: Department of Health Standard for the Cervical Cancer Screening Program Document Ref. Number: DOH/CCSC/SD/1.0 Version: 1.0 Approval Date: 08 May 2018 Effective Date: 13 May 2018 Last Reviewed:

More information

NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS.

NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS. NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS MEASURE ID: NPQR1 MEASURE TITLE: Notification to the Ordering Provider Requesting Myoglobin or CK-MB in the Diagnosis of Suspected

More information

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent

More information

Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear

Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions

More information

Cytopathology. Robert M Genta Pathologie Clinique Université de Genève

Cytopathology. Robert M Genta Pathologie Clinique Université de Genève Cytopathology Robert M Genta Pathologie Clinique Université de Genève Learning objectives At the end of this hour you will know: 1. What cytopathology is 2. How specimens are collected, processed, and

More information

HUMAN PAPILLOMAVIRUS TESTING

HUMAN PAPILLOMAVIRUS TESTING CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018

More information

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING Central Valley Public Health: Women's Way ICD-9-CM (Top 35) ICD-10-CM ICD-10-CM Description COMMENTS V10.3: Personal history of malignant neoplasm of Z85.3

More information

Histopathology: Cervical HPV and neoplasia

Histopathology: Cervical HPV and neoplasia Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about

More information

Evolving Cervical Cancer Screening Options in Clinical Practice

Evolving Cervical Cancer Screening Options in Clinical Practice Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/evolving-cervical-cancer-screening-optionsclinical-practice/8214/

More information

Câncer Cervical e Nutrição 21 trabalhos

Câncer Cervical e Nutrição 21 trabalhos Câncer Cervical e Nutrição 21 trabalhos Cervical Cancer cancer showed that frequent consumption of dark green and yellow vegetables and fruit juices was associated with reduced risk of cervical cancer

More information

Streamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014

Streamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014 Streamlining Protocols-From Strategy to Implementation Doreen Ramogola-Masire Botswana UPenn Partnership 18-20 June 2014 Botswana-UPenn Partnership Partnership between Government of Botswana, University

More information

Diagnostics: The Effect on Evidence Based Clinical Pathways. DNA vs Disease. Bruce K. Pa+erson MD CEO and President, IncellDx, Inc.

Diagnostics: The Effect on Evidence Based Clinical Pathways. DNA vs Disease. Bruce K. Pa+erson MD CEO and President, IncellDx, Inc. Diagnostics: The Effect on Evidence Based Clinical Pathways DNA vs Disease Bruce K. Pa+erson MD CEO and President, IncellDx, Inc. Who Who are we? We Are Cancer First platform to combine proteomic and genomic

More information

L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin

L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin 10 es Journées annuelles de santé publique Palais des congrès de Montréal 23 au 27 octobre 2006 L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du

More information

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%

More information

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa

More information

Cervical Dysplasia and HPV

Cervical Dysplasia and HPV Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk

More information

Human Papillomavirus

Human Papillomavirus Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and

More information

Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease

Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease Nahida Chakhtoura, MD, Leo Twiggs, MD, Timothy DeSantis, MD Claudia Werner, MD, William

More information

Biomed Environ Sci, 2015; 28(1): 80-84

Biomed Environ Sci, 2015; 28(1): 80-84 80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG

More information

BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM

BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it

More information

Cervical Cancer 4/27/2016

Cervical Cancer 4/27/2016 Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about

More information

CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative

CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative June 18 2014 Acknowledgements Anthony Miller Cathy Popadiuk Claude Nadeau Keiko Asakawa Marc Brisson Michael Wolfson Saima

More information

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).

More information

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures

More information

The society for lower genital tract disorders since 1964.

The society for lower genital tract disorders since 1964. The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Hosp Lab Management (HLM) Service. HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow

Hosp Lab Management (HLM) Service. HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow Hosp Lab Management (HLM) Service HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow Women s Healthcare: Demography End of uncertainties Actual Disease Burden: Delhi NCR: FY2012-13

More information

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016 Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,

More information

Estimated New Cancers Cases 2003

Estimated New Cancers Cases 2003 Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz Estimated New Cancers Cases 2003 Images removed due to copyright reasons.

More information

Welcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013

Welcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013 THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download

More information

Gynecologic Cytology-Histology Correlation Guideline

Gynecologic Cytology-Histology Correlation Guideline Gynecologic Cytology- Correlation Guideline George G. Birdsong, MD and Joe W. Walker, Jr., MS, SCT(ASCP) CM Clinical Practice Committee Dr. Birdsong and Mr. Walker are grateful for extensive input from

More information

EVIDENCE REPORT. Ass.-Prof. Dr. Gaby Sroczynski, M.P.H., Univ.-Prof. Dr. Uwe Siebert, M.P.H., M.Sc.

EVIDENCE REPORT. Ass.-Prof. Dr. Gaby Sroczynski, M.P.H., Univ.-Prof. Dr. Uwe Siebert, M.P.H., M.Sc. EVIDENCE REPORT Decision Analysis for the Evaluation of Benefits, Harms and Cost-effectiveness of Different Cervical Cancer Screening Strategies to Inform the S3 Clinical Guideline Prevention of Cervical

More information

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

SESSION J4. What's Next? Managing Abnormal PAPs in 2014 37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines

More information

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding

More information

I have no financial interests to disclose.

I have no financial interests to disclose. Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests

More information

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION Electronic Journal of Pharmacology and Therapy Vol 4, 15-20 (2011) ISSN: 0973-9890 (Available online at wwwtcrjournalscom) Clinical Article ndexed in: ProQuest database Abstract, USA (ProQuest Science

More information